EOLS Stock Analysis

EOLS -  USA Stock  

USD 12.77  0.18  1.43%

The small fall in market price for the last few months could raise concerns from retail investors as the firm it trading at a share price of 12.77 on 1,016,400 in volume. The company directors and management did not add much value to Evolus investors in May. However, diversifying your holdings with Evolus Inc or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.64. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Evolus partners.
Continue to Investing Opportunities.

Search Stock Analysis 

 
Refresh
The Evolus stock analysis report makes it easy to digest most publicly released information about Evolus and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. EOLS stock analysis module also helps to analyze the Evolus price relationship with some important fundamental indicators such as market cap and management efficiency.

EOLS Stock Analysis Notes

About 51.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.83. Evolus Inc had not issued any dividends in recent years. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To learn more about Evolus Inc call Murthy Simhambhatla at 949 284 4555 or check out http://www.evolus.com.

Evolus Quarterly Cost of Revenue

4.91 MillionShare

Evolus Inc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Evolus' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Evolus Inc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Evolus Inc generates negative expected return over the last 90 days
Evolus Inc has high historical volatility and very poor performance
The company currently holds 119.25 M in liabilities with Debt to Equity (D/E) ratio of 1.01, which is about average as compared to similar companies. Evolus Inc has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due.
The entity reported the previous year's revenue of 56.54 M. Net Loss for the year was (163.01 M) with profit before overhead, payroll, taxes, and interest of 38.24 M.
Evolus Inc currently holds about 107.56 M in cash with (57.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.46.
Evolus Inc has a poor financial position based on the latest SEC disclosures
Roughly 51.0% of Evolus shares are held by company insiders
Latest headline from www.equities.com: Evolus Inc falls -4.2000 percent for June 15 - Equities.com

Evolus Inc Upcoming and Recent Events

Earnings reports are used by Evolus to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evolus previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End23rd of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

EOLS Largest EPS Surprises

Earnings surprises can significantly impact Evolus' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-10-29
2020-09-30-0.3667-0.32530.041411 
2018-05-10
2018-03-31-0.36-0.30.0616 
2020-02-25
2019-12-31-0.685-0.51370.171325 
View All Earnings Estimates

Evolus SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Evolus prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Evolus investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Evolus Inc specific information freely available to individual and institutional investors to make a timely investment decision.
12th of May 2021
Financial Statements and Exhibits. Completion of Acquisition or Disposition of Assets
View
28th of April 2021
Financial Statements and Exhibits. Other Events
View
26th of April 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition. Entry into a Material Definitive Agreement
View
1st of April 2021
Unclassified Corporate Event
View
26th of March 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
24th of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
23rd of March 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
1st of March 2021
Unclassified Corporate Event
View

Evolus Thematic Classifications

In addition to having Evolus stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

EOLS Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Evolus is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evolus Inc backward and forwards among themselves. Evolus' institutional investor refers to the entity that pools money to purchase Evolus' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares1.7 M21.8 M
Vanguard Group IncCommon Shares1.1 M14.7 M
Schroder Investment Management GroupCommon Shares895.6 K11.6 M
Invesco LtdCommon Shares560.4 K7.3 M
Awh Capital LpCommon Shares410 K5.3 M
State Street CorpCommon Shares395.4 K5.1 M
Geode Capital Management LlcCommon Shares383.1 KM
Susquehanna International Group LlpCall Options297.6 K3.9 M
Susquehanna International Group LlpPut Options131.3 K1.7 M
Note, although Evolus' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

EOLS Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 673.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evolus's market, we take the total number of its shares issued and multiply it by Evolus's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

EOLS Profitablity

Evolus' profitability indicators refer to fundamental financial ratios that showcase Evolus' ability to generate income relative to its revenue or operating costs. If, let's say, Evolus is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Evolus' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Evolus' profitability requires more research than a typical breakdown of Evolus' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (288.31) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (121.5) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.22.
Last ReportedProjected for 2021
Return on Average Assets(0.78) (0.80) 
Return on Average Equity(9.54) (9.79) 
Return on Invested Capital(1.21) (1.24) 
Return on Sales(2.70) (2.91) 

Management Efficiency

The entity has return on total asset (ROA) of (19.1) % which means that it has lost $19.1 on every $100 spent on asset. This is way below average. Evolus management efficiency ratios could be used to measure how well evolus inc manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/19/2021, Return on Average Assets is likely to drop to -0.8. In addition to that, Return on Average Equity is likely to drop to -9.79. Evolus Assets Non Current are relatively stable at the moment as compared to the past year. Evolus reported last year Assets Non Current of 81.46 Million. As of 06/19/2021, Goodwill and Intangible Assets is likely to grow to about 85.3 M, while Total Assets are likely to drop slightly above 200 M.
Last ReportedProjected for 2021
Book Value per Share(2.16) (2.22) 
Enterprise Value over EBIT(1.00) (1.08) 
Enterprise Value over EBITDA(1.15) (1.23) 
Price to Book Value(1.55) (1.60) 
Tangible Assets Book Value per Share 3.93  3.83 
Enterprise Value165.8 M198.5 M
Tangible Asset Value132.6 M114.7 M

Technical Drivers

As of the 19th of June, Evolus shows the Coefficient Of Variation of 8121.21, mean deviation of 3.7, and Downside Deviation of 6.48. Evolus Inc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Evolus Inc, which can be compared to its rivals. Please confirm Evolus Inc coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Evolus Inc is priced favorably, providing market reflects its regular price of 12.77 per share. Given that Evolus has jensen alpha of 0.0636, we urge you to verify Evolus Inc's prevailing market performance to make sure the company can sustain itself at a future point.

Evolus Inc Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Evolus Inc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evolus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evolus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evolus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Evolus Predictive Daily Indicators

Evolus intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evolus stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Evolus Forecast Models

Evolus time-series forecasting models is one of many Evolus' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Evolus' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Evolus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Evolus stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling EOLS shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Evolus. By using and applying EOLS Stock analysis, traders can create a robust methodology for identifying EOLS entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(2.56) (2.76) 
Gross Margin 0.68  0.66 
Profit Margin(2.88) (3.11) 
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Current EOLS Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. EOLS analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. EOLS analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
17.14Buy7Odds
Evolus Inc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most EOLS analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand EOLS stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Evolus Inc, talking to its executives and customers, or listening to EOLS conference calls.
EOLS Analyst Advice Details

EOLS Stock Analysis Indicators

Evolus Inc stock analysis indicators help investors evaluate how Evolus stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Evolus shares will generate the highest return on investment. By understating and applying Evolus stock analysis, traders can identify Evolus position entry and exit signals to maximize returns.
Quick Ratio0.65
Fifty Two Week Low2.85
Revenue Growth5.80%
Shares Short Prior Month2.94M
Average Daily Volume Last 10 Day438.74k
Average Daily Volume In Three Month957.27k
Shares Percent Shares Out8.42%
Gross Margins67.63%
Short Percent Of Float11.29%
Forward Price Earnings-31.15
Float Shares27.13M
Fifty Two Week High17.38
Enterprise Value To Ebitda-6.58
Fifty Day Average10.06
Two Hundred Day Average8.83
Enterprise Value To Revenue7.18
Continue to Investing Opportunities. Note that the Evolus Inc information on this page should be used as a complementary analysis to other Evolus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Evolus Stock analysis

When running Evolus Inc price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
The market value of Evolus Inc is measured differently than its book value, which is the value of EOLS that is recorded on the company's balance sheet. Investors also form their own opinion of Evolus' value that differs from its market value or its book value, called intrinsic value, which is Evolus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolus' market value can be influenced by many factors that don't directly affect Evolus Inc underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolus' value and its price as these two are different measures arrived at by different means. Investors typically determine Evolus value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.